好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Real-world Interaction Between Pregnancy and Generalized Myasthenia Gravis
Neuromuscular and Clinical Neurophysiology (EMG)
S34 - Updates on Myasthenia Gravis (1:48 PM-2:00 PM)
005
To compare incremental treatment use, myasthenia gravis (MG) exacerbations, crises, and related costs among pregnant versus non-pregnant women with generalized MG (gMG).
MG symptoms may flare up during pregnancy increasing the risk of respiratory failure and affecting pregnancy outcomes. With emerging targeted treatment options, understanding the interaction between pregnancy and gMG may help identify unmet needs and guide management decisions.
Pregnant and non-pregnant women with gMG were identified from Komodo Research Database (01/2017-09/2023). In pregnant cohort, the baseline period included 12 months pre-conception (index date), and the follow-up period included pregnancy plus 6 months post-partum. Non-pregnant cohort (random index date) was matched to pregnant cohort 10:1 based on lengths of the baseline and follow-up periods. Cohorts were weighted on baseline characteristics using entropy balancing. Treatment utilization, MG exacerbations, crises, and related costs (USD2023; per-patient-per-month) were compared during the follow-up period between weighted cohorts.
97 pregnant and 970 non-pregnant women with gMG were included. During the follow-up period, pregnant cohort had fewer days with treatment supply per month compared to non-pregnant cohort, with following mean differences (MDs): non-steroidal immunosuppressants (MD: -4.33), monoclonal antibodies (MD: -1.49), and complement-5 inhibitors (MD: -1.18; all p<0.001). While the pregnant and non-pregnant cohorts had a similar likelihood of exacerbation (odds ratio [OR]: 1.25; p=0.391), the pregnant cohort was more likely than the non-pregnant cohort to experience a crisis (OR: 3.90; p=0.027). Pregnant cohort had $3,930 lower MG-related pharmacy costs (p=0.004), but MG exacerbation- and crisis-related costs were comparable between cohorts.
Results suggest unmet needs in treating gMG during pregnancy, as evidenced by significantly lower supply and costs for gMG-related treatments alongside higher likelihood of experiencing MG crisis compared to non-pregnant women. Upcoming analyses in pregnant women with and without gMG may provide additional insights into the interaction between pregnancy and gMG.
Authors/Disclosures
Louis Jackson, PharmD (Janssen)
PRESENTER 		Dr. Jackson has received personal compensation for serving as an employee of Johnson and Johnson.
Maryia Zhdanava Maryia Zhdanava has received personal compensation for serving as an employee of Analysis Group.
Jacqueline Pesa (Janssen) Jacqueline Pesa has received personal compensation for serving as an employee of Johnson and Johnson.
Porpong Boonmak (Analysis Group, Inc.) Porpong Boonmak has received personal compensation for serving as an employee of Analysis Group, Inc..
Melanie Jacobson, PhD Dr. Jacobson has received personal compensation for serving as an employee of Janssen R&D.
Beatrice Libchaber Miss Libchaber has received personal compensation for serving as an employee of Analysis Group, Inc..
Francesca Lee Miss Lee has received personal compensation for serving as an employee of Analysis Group, Inc..
Dominic Pilon (Analysis Group, Inc.) Dominic Pilon has received personal compensation for serving as an employee of Analysis Group, Inc..
Zia U. Choudhry, MD, PhD (JOHNSON AND JOHNSON) Dr. Chaudhry has received personal compensation for serving as an employee of Johnson & Johnson. Dr. Chaudhry has received personal compensation for serving as an employee of Takeda Pharmaceuticals.
Neelam Goyal, MD, FAAN (Stanford University) Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Goyal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Janssen. Dr. Goyal has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Goyal has received research support from Argenx.